Clerisy Corporation, through development and delivery of its revolutionary medical solutions is poised to become a leader in health and wellness channels.
This Information Memorandum (“Memorandum”) has been prepared to showcase the Company’s products and their expected financial impact on the Company and its shareholders for the period 2018-2022. The Company was formed as a corporation in New York in 2005 with offices in New York and Southern California provides revolutionary medical solutions for use across a variety of vertical channels.
Evaluate Pharma, in its annual World Preview report, projects a global growth rate for the pharma industry of 6.3% CAGR through 2022.
Clerisy NeuroNasal Strips® are a world first, globally patented, FDA approved Class 1, non-significant risk medication delivery device for use by consumers over the age of 12.
The Company is currently managed by seasoned business and sector professionals dedicated to the success of the Company and efficient execution of its planned operations
Chief Executive Officer
Entrepreneurial business development and investment banking business career that spans 37 years. Experience includes Imax entertainment theaters, apparel manufacturing, advanced semiconductor memory chip development and manufacturing, renewable energy systems, reverse osmosis water treatment and hydroponic plant cultivation. Extensive experience in capital markets including IPOs, mergers and acquisitions. Founder, Chairman & CEO of 6 previously public companies in Australia, US & UK.
Chief Financial Officer
Senior financial executive who brings over 30 years of financial management, compliance, operational and managerial experience. Experience includes Chief Financial Officer of public and private companies. Broad-ranging experience in the development and management of financial controls, financial reporting, and treasury functions in a growth company environment and experience in directing financial and operational activities of overseas facilities. Qualified as a CPA in 1979 with Price Waterhouse & Co, now part of PricewaterhouseCoopers LLP in Los Angeles. Earned a Bachelor of Arts and Master of Business Administration degrees from the University of Southern California.
Clerisy Corporation (the “Company” or “Clerisy”) a New York Corporation, is offering one hundred (100) of its 6% Class A Convertible Debentures due in 60 months, consisting of Debentures totaling an aggregate principal face amount not exceeding Five Million Dollars (U.S. $5,000,000.00); which Debentures are being purchased at 100% of face value (See Attached Exhibit A). The Class A Convertible Debentures is also referred to throughout as “Class A unit.”
Clerisy Corporation — Geza Molnar — 31642 Coast Highway, Suite 200 — Laguna Beach, CA 92651 — (949) 456-3972
The Clerisy Corporation 506(c) Investor Portal provides the opportunity for you to become approved as a “prospect", and learn more about our investment opportunity. You will have:
We will upgrade your account to “Investor” level access, which provides all of the prospect level access and: